Get the Stockscreener App
0.6811
0.88%
-0.0182
Dermata Therapeutics Inc stock is traded at $0.6811, with a volume of 21,533.
It is down -0.88% in the last 24 hours and up +10.80% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$0.6993
Open:
$0.708
24h Volume:
21,533
Relative Volume:
0.16
Market Cap:
$4.34M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.0318
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
+5.95%
1M Performance:
+10.80%
6M Performance:
-40.76%
1Y Performance:
-73.13%
1-Day Range:
$0.681
$0.71
1-Week Range:
$0.6415
$0.75
52-Week Range:
$0.5739
$3.79
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
0.6811 | 4.56M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.31 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.19 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.49 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
594.16 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.16 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Should I buy Dermata Therapeutics Inc. stock before earningsTremendous wealth creation - jammulinksnews.com
What drives Dermata Therapeutics Inc. stock priceSky-high return potential - Autocar Professional
Is Dermata Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
What drives Dermata Therapeutics Inc. Equity Warrant stock priceConsistent triple returns - Autocar Professional
What analysts say about Dermata Therapeutics Inc. Equity Warrant stockHigh-yield market plays - PrintWeekIndia
What analysts say about Dermata Therapeutics Inc. stockFree Trend-Following Techniques - jammulinksnews.com
Is Dermata Therapeutics Inc. Equity Warrant a good long term investmentHigh-profit trading signals - jammulinksnews.com
Published on: 2025-07-22 22:23:22 - jammulinksnews.com
Dermata Therapeutics Inc. Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
Dermata Therapeutics Inc. Equity Warrant Stock Analysis and ForecastRecord-breaking capital gains - jammulinksnews.com
Dermata Therapeutics shareholders approve reverse stock split and key proposals By Investing.com - Investing.com South Africa
Dermata Therapeutics shareholders approve reverse stock split and key proposals - Investing.com
Dermata Therapeutics Holds Annual Stockholders Meeting - TipRanks
What makes Dermata Therapeutics Inc. stock price move sharplyPro Trader Stock Focus - Newser
How Dermata Therapeutics Inc. Equity Warrant stock performs during market volatilityFree Membership Group - Newser
What makes Dermata Therapeutics Inc. Equity Warrant stock price move sharplyFree Stock Tips Group - Newser
Why Dermata Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
Why Dermata Therapeutics Inc. Equity Warrant stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
How Dermata Therapeutics Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):